Search
for
Sort by
Research 30 of 400
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- Olorofim Effectively Eradicates Dermatophytes <i>In Vitro</i> and <i>In Vivo</i>
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- Teriflunomide in multiple sclerosis: an update
- “Nail loss after teriflunomide treatment: A new potential adverse event”
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
- Teriflunomida and hair disorders
- Tether-induced tenosynovitis: The importance of an intact skin barrier
- Targeting nonmelanoma skin cancer using selective photothermolysis with 595 nm pulsed dye laser: Outcomes of 1080 cases
- Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- New treatments for rheumatoid arthritis
- Hair Loss Associated with Teriflunomide Treatment
- Leflunomide-Induced Cutaneous Ulcers: A Rare Diagnostic Conundrum
- 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- Topical delivery of nanoemulsions for skin cancer treatment
- Effects of SLC45A2 and GPNMB on Melanin Deposition Based on Transcriptome Sequencing in Chicken Feather Follicles
- Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry
- Systemic Circulating Leptin – Aiding New Dimension of Immune-Related Skin Carcinogenesis and Lipid Metabolism
- Bioprospecting of Potential Inhibitors of 5alpha Reductase 2 Inhibitors from Relevant Ethno-pharmacological Plants via In Silico Techniques
- Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968)
- Effect of <i>Trigonella foenum-graecum</i> Linn. (seeds) and <i>Butea monosperma</i> Lam. (flowers) on chemotherapy-induced alopecia